XORTX Gross Profit from 2010 to 2024

XRTX Stock

USD 1.21 0.02 1.68%

XORTX Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit XORTX Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-142 K

Current Value

-134.9 K

Quarterly Volatility

42.5 K

Credit Downgrade

Yuan Drop

Covid

Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 2.6 M or Total Operating Expenses of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.

Check out the analysis of XORTX Therapeutics Correlation against competitors.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of XORTX Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of XORTX Therapeutics minus its cost of goods sold. It is profit before XORTX Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. XORTX Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

XORTX Gross Profit Regression Statistics

	Arithmetic Mean	(39,653)
	Coefficient Of Variation	(107.28)
	Mean Deviation	31,084
	Median	(20,439)
	Standard Deviation	42,539
	Sample Variance	1.8B
	Range	124.1K
	R-Value	(0.67)
	Mean Square Error	1.1B
	R-Squared	0.45
	Significance	0.01
	Slope	(6,407)
	Total Sum of Squares	25.3B

XORTX Gross Profit History

	2024	-134.9 K
	2023	-142 K
	2022	-75.3 K
	2021	-17.9 K

Other Fundumenentals of XORTX Therapeutics

Gross Profit Margin

XORTX Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Net Tangible Assets	Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.98	-0.99	-0.5	0.53	0.76	0.89	1.0	-0.43	-0.74	0.91	0.56	-0.15	0.97	-0.62	1.0	0.84	0.73	0.92	-0.15	0.16
Total Stockholder Equity	0.98		-0.98	-0.49	0.39	0.71	0.8	0.98	-0.45	-0.75	0.92	0.56	-0.17	0.99	-0.58	0.99	0.83	0.73	0.93	-0.17	0.22
Net Debt	-0.99	-0.98		0.44	-0.51	-0.73	-0.88	-0.99	0.38	0.7	-0.89	-0.48	0.12	-0.97	0.54	-0.99	-0.79	-0.67	-0.89	0.12	-0.12
Retained Earnings	-0.5	-0.49	0.44		-0.36	-0.77	-0.37	-0.47	0.76	0.87	-0.76	-0.87	0.8	-0.48	0.78	-0.52	-0.85	-0.86	-0.74	0.8	-0.83
Accounts Payable	0.53	0.39	-0.51	-0.36		0.67	0.83	0.52	-0.23	-0.3	0.33	0.44	0.11	0.34	-0.56	0.49	0.53	0.35	0.37	0.11	-0.11
Net Receivables	0.76	0.71	-0.73	-0.77	0.67		0.74	0.74	-0.65	-0.78	0.78	0.77	-0.35	0.65	-0.72	0.75	0.9	0.75	0.81	-0.35	0.48
Total Liab	0.89	0.8	-0.88	-0.37	0.83	0.74		0.89	-0.27	-0.54	0.68	0.46	0.08	0.78	-0.57	0.86	0.71	0.56	0.71	0.08	-0.08
Total Current Assets	1.0	0.98	-0.99	-0.47	0.52	0.74	0.89		-0.42	-0.71	0.89	0.54	-0.13	0.97	-0.61	1.0	0.82	0.71	0.9	-0.13	0.13
Short Term Debt	-0.43	-0.45	0.38	0.76	-0.23	-0.65	-0.27	-0.42		0.58	-0.61	-0.84	0.56	-0.43	0.83	-0.46	-0.73	-0.67	-0.58	0.56	-0.56
Intangible Assets	-0.74	-0.75	0.7	0.87	-0.3	-0.78	-0.54	-0.71	0.58		-0.91	-0.71	0.65	-0.73	0.62	-0.75	-0.89	-0.95	-0.92	0.65	-0.71
Net Tangible Assets	0.91	0.92	-0.89	-0.76	0.33	0.78	0.68	0.89	-0.61	-0.91		0.7	-0.53	0.92	-0.68	0.93	0.91	0.87	0.98	-0.53	0.53
Long Term Debt	0.56	0.56	-0.48	-0.87	0.44	0.77	0.46	0.54	-0.84	-0.71	0.7		-0.48	0.54	-0.94	0.57	0.9	0.78	0.72	-0.48	0.65
Deferred Long Term Liab	-0.15	-0.17	0.12	0.8	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48		-0.21	0.41	-0.2	-0.44	-0.61	-0.44	1.0	-0.8
Net Invested Capital	0.97	0.99	-0.97	-0.48	0.34	0.65	0.78	0.97	-0.43	-0.73	0.92	0.54	-0.21		-0.58	0.98	0.81	0.71	0.92	-0.21	0.21
Short Long Term Debt	-0.62	-0.58	0.54	0.78	-0.56	-0.72	-0.57	-0.61	0.83	0.62	-0.68	-0.94	0.41	-0.58		-0.63	-0.86	-0.76	-0.67	0.41	-0.42
Net Working Capital	1.0	0.99	-0.99	-0.52	0.49	0.75	0.86	1.0	-0.46	-0.75	0.93	0.57	-0.2	0.98	-0.63		0.85	0.75	0.93	-0.2	0.19
Common Stock	0.84	0.83	-0.79	-0.85	0.53	0.9	0.71	0.82	-0.73	-0.89	0.91	0.9	-0.44	0.81	-0.86	0.85		0.9	0.94	-0.44	0.58
Property Plant Equipment	0.73	0.73	-0.67	-0.86	0.35	0.75	0.56	0.71	-0.67	-0.95	0.87	0.78	-0.61	0.71	-0.76	0.75	0.9		0.88	-0.61	0.6
Capital Stock	0.92	0.93	-0.89	-0.74	0.37	0.81	0.71	0.9	-0.58	-0.92	0.98	0.72	-0.44	0.92	-0.67	0.93	0.94	0.88		-0.44	0.54
Current Deferred Revenue	-0.15	-0.17	0.12	0.8	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48	1.0	-0.21	0.41	-0.2	-0.44	-0.61	-0.44		-0.8
Short Term Investments	0.16	0.22	-0.12	-0.83	-0.11	0.48	-0.08	0.13	-0.56	-0.71	0.53	0.65	-0.8	0.21	-0.42	0.19	0.58	0.6	0.54	-0.8

Click cells to compare fundamentals

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	-142 K	-134.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC